Abstract
Purpose:
New tetrahydrocannabinolic acid (THCA) derivatives ALAM027 and ALAM108 were proposed for the treatment of the pancreatic cancer disease.
Methods:
The in vitro effect of new cannabinoids ALAM027 and ALAM108 was tested against PANC-1 and AsPC1 cell lines by CellTiter Glo assay. Pancreatic cancer xenograft model was used for the in vivo anticancer activity study of these compounds on PANC-1 cells.
Results:
The in vitro study of new cannabinoids showed greater activity of ALAM108 than ALAM027 both for PANC-1 and AsPC-1 cells. The in vivo study of new cannabinoids on PANC-1 cells showed that their oral administration was effective in reducing tumor volume and tumor weight, and did not lead to any discomfort and weight loss of mice.
Conclusion:
The cannabinoids ALAM108 and ALAM027 inhibited the tumor growing 1.6–2 times in mice with human PANC-1 cells
